After closing a remarkable year, we are taking a moment to reflect on the incredible journey we’ve shared as a team and acknowledge the collective efforts that have propelled our company to new heights. Amidst challenges, uncertainties, and opportunities for our nascent industry, we have not only persevered but excelled in various aspects of our operations.
As we prepare to write-in a new chapter, we want to take a moment to celebrate the achievements that defined a successful 2023 for Newel Health! From groundbreaking projects to transformative initiatives, each milestone reached was a testament to the hard work and passion that each member of our team has poured into their respective roles.
We are particularly proud of the following:
- Acquisition of ISO Certifications: The company successfully obtained three critical certifications: ISO 9001 (Quality Management System), ISO 27001 (Information Security), and ISO 13485 (Medical Devices Design & Development). These certifications demonstrate the company’s commitment to excellence, regulatory compliance, and patient safety.
- Porting of H.Core to PHP 8.2: The H.Core platform, the company’s core technology infrastructure, was successfully ported to the latest PHP version, PHP 8.2. This upgrade ensures the platform’s compatibility with modern technologies and facilitates future development.
- We also added several new features, one of which is to be highlighted for its importance: the new Notification and Engagement Engine
- Establishment of the Data Science Team: The company set up a dedicated Data Science Team, demonstrating its commitment to leveraging data analytics to enhance its products and services. The team’s expertise will be instrumental in analyzing clinical trial data, improving user experience, and optimizing business decisions.
- Initiation of Clinical Trial in PD: The company launched its first clinical trial in Parkinson’s disease, involving 60 patients. This trial is crucial for evaluating the efficacy and safety of the company’s products in treating PD patients. Soturi, has already accumulated a huge amount hour of data. This substantial data collection provides valuable insights into patient behavior and health patterns other than our main source to develop our own algorithm for detecting motion symptoms.
- Public Testing of Amicomed: The company conducted a “public” testing of Amicomed, attracting more than 1,000 users and generating over 3,000 blood pressure measurements. This pilot testing allowed for gathering feedback from a wider audience and refining the app’s functionality.
- Data-Driven Report Development: The company compiled its first comprehensive report on the data gathered through Amicomed, providing valuable insights into patient behavior and the effectiveness of the app.
- Gold Sponsors at Frontiers Health 2023: On November 8-10 in the vibrant city of Rome, our team joined the global conference, contributing to the outstanding community of health innovators and inspiring content.
- Collaboration with Healthcare Institutions: The company established partnerships with several hospitals and universities, fostering collaboration and knowledge exchange in the medical field.
- Grant Acquisitions for Amicomed and Soturi The company secured two grants from Regione Campania for Amicomed (with a new application still pending) and a noteworthy grant from the Michael J. Fox Foundation (USD 2.5 million) for Soturi, demonstrating external recognition and support for our innovative technologies.
With a strong year behind us, we are determined that 2024 will bring even more energy and determination for our team and partners to push beyond what we thought was possible. Our dedication and passion make us confident that we’ll not only meet our 2024 goals but exceed them, making Newel Health a standout success once again this year.
So, here’s to a year of fresh challenges, ongoing growth, and incredible achievements.
